News Releases

Date	Title and Summary	View
May 18, 2020	Janssen Presents First Data from Phase 1 Study of BCMAxCD3 Bispecific Teclistamab in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
May 13, 2020	ERLEADA® (apalutamide) Significantly Improved Overall Survival in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
May 13, 2020	Janssen’s BCMA CAR-T Therapy JNJ-4528 Showed Early, Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
May 13, 2020	Johnson & Johnson to Participate in Bernstein's 36th Annual Strategic Decisions Virtual Conference
May 08, 2020	Biosense Webster Unveils Late-Breaking Results from PRECEPT Study in Patients with Persistent Atrial Fibrillation
May 01, 2020	U.S. Food and Drug Administration Approves DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a New Subcutaneous Formulation of Daratumumab in the Treatment of Patients with Multiple Myeloma
Apr 30, 2020	CHMP Grants Positive Opinion for DARZALEX®▼(daratumumab) Subcutaneous Formulation for the Treatment of Patients with Multiple Myeloma
Apr 27, 2020	Federal Judge Excludes Certain Plaintiff Expert Testimony from Talc Ovarian Cancer Trials, Deeming Them Not Scientifically Sound
Apr 24, 2020	Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
Apr 23, 2020	Johnson & Johnson Announces Collaboration to Expand Manufacturing Capabilities For its COVID-19 Vaccine Candidate in Support of the Company's Goal to Supply More Than One Billion Vaccine Doses Globally Company Signs Agreement with Emergent BioSolutions in the U.S. As Part of its Investment First in Series of Anticipated Strategic Collaborations Designed to Further the Company's Goal of Ensuring Global Supply of a Safe and Effective Vaccine for COVID-19 NEW BRUNSWICK, N.J.